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Abstract
Background:  Some patients will experience more or less benefit from treatment than the
averages reported from clinical trials; such variation in therapeutic outcome is termed
heterogeneity of treatment effects (HTE). Identifying HTE is necessary to individualize treatment.
The degree to which heterogeneity is sought and analyzed correctly in the general medical
literature is unknown. We undertook this literature sample to track the use of HTE analyses over
time, examine the appropriateness of the statistical methods used, and explore the predictors of
such analyses.
Methods: Articles were selected through a probability sample of randomized controlled trials
(RCTs) published in Annals of Internal Medicine, BMJ, JAMA, The Lancet, and NEJM during odd
numbered months of 1994, 1999, and 2004. RCTs were independently reviewed and coded by two
abstractors, with adjudication by a third. Studies were classified as reporting: (1) HTE analysis,
utilizing a formal test for heterogeneity or treatment-by-covariate interaction, (2) subgroup analysis
only, involving no formal test for heterogeneity or interaction; or (3) neither. Chi-square tests and
multiple logistic regression were used to identify variables associated with HTE reporting.
Results: 319 studies were included. Ninety-two (29%) reported HTE analysis; another 88 (28%)
reported subgroup analysis only, without examining HTE formally. Major covariates examined
included individual risk factors associated with prognosis, responsiveness to treatment, or
vulnerability to adverse effects of treatment (56%); gender (30%); age (29%); study site or center
(29%); and race/ethnicity (7%). Journal of publication and sample size were significant independent
predictors of HTE analysis (p < 0.05 and p < 0.001, respectively).
Conclusion:  HTE is frequently ignored or incorrectly analyzed. An iterative process of
exploratory analysis followed by confirmatory HTE analysis will generate the data needed to
facilitate an individualized approach to evidence-based medicine.
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Background
Randomized controlled trials (RCTs) are the cornerstone
of evidence-based medicine. Such trials rely on random
assignment to alternative treatment groups to control for
baseline patient factors that could affect outcomes. The
resulting estimate of the average treatment effect is an
average of the individual treatment effects (ITEs) for partic-
ipants in the study. While estimates of the average treat-
ment effect are generally useful, some treated individuals,
both within and outside of clinical trials, will experience
more or less benefit than the reported average. Such vari-
ation in treatment effect is termed heterogeneity of treat-
ment effects (HTE) [1,2].
HTE may be quantitative (subgroup effects in the same direc-
tion as the average effect but varying in magnitude) or qual-
itative (treatment effects in different directions in different
subgroups, where treatment is beneficial in some subgroups
and harmful in others). The prevalence of HTE is unknown
and perhaps unknowable, but highly variable treatment
response rates for many common conditions suggest it is
substantial. [3,4] For example, Allen Roses, the vice president
of genetics at GlaxoSmithKline, has stated, "Our drugs don't
work on most patients" [5]. Several empirical demonstra-
tions of HTE have recently been published, including studies
of ischemic stroke [6], risk reduction by carotid endarterec-
tomy [7,8], and diabetes [9]. While qualitative HTE may be
uncommon, quantitative HTE should not be dismissed,
because even modest variations in the magnitude of net
treatment benefits may have important implications for
patient care and cost-effectiveness.
HTE can be assessed in several ways. The most direct
approach is the n-of-1 clinical trial, which assigns individ-
ual patients to receive alternative treatment in a randomly
predetermined sequence [10,11]. Results from a series of
such trials can be aggregated to assess heterogeneity in the
population. However, n-of-1 trials are applicable to a rel-
atively small subset of conditions and treatments [10,11]
and are subject to random within-patient variability (thus
requiring a careful design and repeated crossovers)
[12,13]. A second approach is to stratify patients accord-
ing to risk of disease-related adverse events [14,15]. A
third approach, typically performed for purposes of
hypothesis generation rather than testing, entails a careful
examination of subgroups within RCTs.
Subgroup analysis can be perilous. Real effects can be
missed because of inadequate statistical power [16,17],
and reported effects may be spurious because of the per-
formance of multiple statistical tests (13–16) and/or due
to random intra-individual variability [12,13]. Random
intra-individual variability is especially problematic
because it is not possible to estimate this variability in par-
allel group trials, the most common type of clinical trial
design. In parallel group trials, participants are only rand-
omized to one treatment and do not crossover to alterna-
tive treatments. As such, it is not possible to estimate any
variation that occurs within a participant. In recognition of
the drawbacks of subgroup analysis, the Consolidated
Standards of Reporting Trials (CONSORT) statement
warns that subgroup analyses, especially post hoc sub-
group comparisons, "do not have great credibility" [18].
On the other hand, it has been claimed that nearly every-
thing we have learned from epidemiology resulted from
subgroup analysis [19]. While this conclusion applies most
obviously to observational studies, careful scrutiny of sub-
group-specific effects in randomized trials has generated
important new hypotheses and sometimes directly influ-
enced practice. Nevertheless, subgroup analyses are not
always performed correctly. Some studies (e.g. [20-23])
report results by subgroups, without any statistical testing or
interval estimation for the difference across  subgroups;
these studies do not provide quantitative information on
HTE per se. Other studies report p-values corresponding to
each subgroup, subsequently claiming that the treatment
effect differs across subgroups because it is statistically sig-
nificant in one subgroup and not in another [24]. However,
both treatment effect and sample size influence the p-value,
such that similar effect sizes within each subgroup might
generate markedly different p-values. Instead of comparing
the p-values across subgroups, the appropriate way to iden-
tify significant HTE is to make statistical comparisons for
treatment effects across subgroups, using a test for heteroge-
neity or interaction [7,17,18,25-27].
The tension between needing to understand HTE and
lacking the statistical power to properly examine it
presents difficulties for researchers, clinicians, and
patients. While some experts have offered general encour-
agement to perform more HTE analyses [28,29], the liter-
ature is relatively silent on how to manage the risks of
over- and under-testing. Kraemer et al. [25,30,31] have
suggested a sequential approach that could shed light on
possible HTE. Defining treatment modifiers as factors that
influence the treatment effect size across subgroups, they
propose that all RCTs use exploratory interaction analyses as
a method to generate hypotheses regarding moderators of
treatment effects. The presence of strong moderator effects
would encourage future researchers to perform ade-
quately powered confirmatory studies stratified prospec-
tively on these moderators. While the proposal of
Kraemer et al. makes sense, several small reviews, most
published well before the revised CONSORT statement,
suggest that testing for HTE is reported in only 25% to
50% of RCTs [18,27,32-35].
We undertook the current review of the prevalence of HTE
analyses in a comparatively larger sample of articles pub-Trials 2009, 10:43 http://www.trialsjournal.com/content/10/1/43
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Article selection for systemic review of heterogeneity of treatment effect in RCTs published in five general medical journals Figure 1
Article selection for systemic review of heterogeneity of treatment effect in RCTs published in five general 
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Table 1: Characteristics of included articles (n = 303) and RCTs described in these articles (n = 319)*
Characteristic Articles Represented # RCTs Included
Journal of publication
Annals 30 (10) 30 (9)
BMJ 43 (14) 47 (15)
JAMA 45 (15) 50 (16)
Lancet 97 (32) 101 (32)
NEJM 88 (29) 91 (29)
Year of publication
1994 86 (28) 91 (29)
1999 102 (34) 106 (33)
2004 115 (38) 122 (38)
Medical condition under study
Cardiovascular 69 (23) 74 (23)
Infectious Disease 62 (20) 70 (22)
Cancer 41 (14) 42 (13)
Psychiatry/Neurology 25 (8) 25 (8)
Other 106 (35) 108 (34)
First author's study region
North America 115 (38) 121 (38)
Other 188 (62) 198 (62)
Study design
Parallel - 304 (95)
Crossover - 15 (5)
Analysis reported
HTE analysis - 92 (29)
Subgroup without statistical comparison - 88 (28)
None - 139 (44)
Sample size 262 (101 – 708)
- [6–41,000]
Abbreviations: RCTs, randomized controlled trials; BMJ, British Medical Journal; JAMA, Journal of the American Medical Association; NEJM, New 
England Journal of Medicine; HTE, heterogeneity of treatment effects.
*Discrete data are expressed as No. (%); continuous values are presented as median (inter-quartile range) [range].Trials 2009, 10:43 http://www.trialsjournal.com/content/10/1/43
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Table 2: HTE reporting by study characteristics (n = 319 RCTs in 303 articles)
Characteristic N No. (%) Reporting HTE No. (%) Reporting Either subgroup or HTE
Journal of publication † †
Annals 30 11 (37) 16 (53)
BMJ 47 9 (19) 18 (38)
JAMA 50 21 (42) 33 (66)
Lancet 101 21 (21) 53 (53)
NEJM 91 30 (33) 60 (66)
Year of publication
1994 91 20 (22) 47 (52)
1999 106 30 (28) 62 (58)
2004 122 42 (34) 71 (58)
Medical condition under study ‡
Cardiovascular 74 21 (28) 43 (58)
Infectious disease 70 25 (36) 48 (69)
Cancer 42 15 (36) 30 (71)
Psychiatry/Neurology 25 7 (28) 12 (48)
Other 108 24 (22) 47 (44)
First author's study region ‡ ‡
North America 121 47 (39) 80 (66)
Other 198 45 (23) 100 (51)
Study design ||
Parallel 304 89 (29) 177 (58)
Crossover 15 3 (20) 3 (20)
Sample size ** **
Quintile 1 (median = 37) 64 9 (14) 18 (28)
Quintile 2 (median = 124) 64 7 (11) 29 (45)
Quintile 3 (median = 263) 64 22 (34) 45 (70)
Quintile 4 (median = 549) 64 21 (33) 40 (63)
Quintile 5 (median = 1560) 63 33 (52) 48 (76)
Abbreviations: HTE, heterogeneity of treatment effects; RCTs, randomized controlled trials; BMJ, British Medical Journal; JAMA, Journal of the 
American Medical Association; NEJM, New England Journal of Medicine.
†p < 0.05 by Pearson Chi-square test
‡p < 0.01 by Pearson Chi-square test
§p < 0.05 by Fisher's exact test
||p < 0.01 by Fisher's exact test
¶p < 0.05 by Mantel-Hantzel test for trend
**p < 0.0001 by Mantel-Hantzel test for trendTrials 2009, 10:43 http://www.trialsjournal.com/content/10/1/43
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lished in the general medical literature in order to assess
trends over time, examine the appropriateness of the sta-
tistical methods used, and explore the predictors of such
analyses. A persistently low rate of appropriate HTE or
interaction analysis would suggest missed opportunities
for identifying HTE.
Methods
Overview
We conducted a literature sample of RCTs published in
five prominent general medical journals during 1994,
1999, and 2004. The search strategy and abstraction forms
incorporated input from a Project Advisory Committee.
Human Subjects committee approval was not required.
The study was funded by Pfizer, Inc., under a contract to
the academic institutions involved. However, the investi-
gators were solely responsible for all aspects of study
design, data collection and analysis, and result reporting.
Data Sources and Searches
Using PubMed, we searched for RCTs published in the
Annals of Internal Medicine, British Medical Journal, Journal
of the American Medical Association, Lancet, and New Eng-
land Journal of Medicine during odd numbered months in
1994, 1999, and 2004 (Figure 1). These prominent medi-
cal journals were selected because they have a broad read-
ership, are the publication venue for many landmark
studies, and have disproportionate influence on medical
research and practice [36,37]. During the period of inter-
est, 4,863 articles appeared in these journals. Of these,
907 were excluded for having publication types of "biog-
raphy", "case report", "editorial", "news", "letters", "com-
ments", and "patient education handout". The remaining
3,956 articles were then restricted to include only journal
articles and reviews, thereby eliminating all articles with-
out a research abstract (n = 1,815 articles excluded). To
assess the validity of these exclusions, one of the investi-
gators reviewed a 5% random sample of the 2,722
excluded articles, resulting in no questionable exclusions.
Finally, the remaining 2,141 articles were subdivided into
two groups: those with "clinical trial" as a publication
type (n = 541) and those without (n = 1,600). The 1,600
articles without clinical trial as publication type were
excluded after they were examined by one investigator,
and a 10% random sample was additionally examined by
a second investigator, without finding any clinical trials.
The 541 articles reporting on clinical trials were randomly
sorted into 10 batches of 54 articles each (the tenth batch
contained 55 articles). Seven batches, or 379 articles, were
randomly selected and individually reviewed by two
investigators to determine final inclusion status. Discrep-
ancies were resolved in consultation with a third investi-
gator.
Study Selection
To be included in our sample, a trial had to meet the fol-
lowing criteria: (1) human study population; (2) parallel
group RCT (including matched pair trials) or a crossover
Table 3: Logistic regression results examining predictors of HTE 
or subgroup analysis
Predict HTE analysis
Condition OR (95% CI)*
Journal of publication †
BMJ 1.00 [reference]
Annals 4.22 (1.18–15.08)
JAMA 4.40 (1.43–13.53)
Lancet 1.44 (0.55–3.77)
NEJM 2.36 (0.85–6.56)
Year of publication
2004 1.00 [reference]
1999 0.88 (0.47–1.66)
1994 0.83 (0.41–1.67)
Medical condition under study
Other 1.00 [reference]
Cardiovascular 1.07 (0.50–2.32)
Infectious disease 1.38 (0.66–2.89)
Cancer 1.13 (0.47–2.71)
Psychiatry/Neurology 2.85 (0.91–8.92)
First author's study region
Other 1.00 [reference]
North America 1.23 (0.67–2.29)
Sample size ‡
Quintile 1 (median = 37) 1.00 [reference]
Quintile 2 (median = 124) 0.72 (0.24–2.14)
Quintile 3 (median = 263) 4.17 (1.62–10.74)
Quintile 4 (median = 549) 3.08 (1.20–7.91)
Quintile 5 (median = 1560) 7.55 (2.95–19.33)
Abbreviations: HTE, heterogeneity of treatment effects; OR, odds 
ratio; CI, confidence interval; BMJ, British Medical Journal; JAMA, 
Journal of the American Medical Association; NEJM, New England 
Journal of Medicine
*Adjusted for all other variables in the model
†Significant at p < 0.05 for a combined Wald Chi-square test
‡Significant at p < 0.001 for a combined Wald Chi-square testTrials 2009, 10:43 http://www.trialsjournal.com/content/10/1/43
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RCT (including n-of-1 trials); and (3) individual patient
or time (treatment episode) within patient (for crossover
trials) was the unit of randomization. We excluded trials
that used cluster randomization because these trials gen-
erally focus on group- or organizational-level treatment
effects.
Data Extraction, Measures, and Hypotheses
All data were abstracted independently by two trained
abstractors. Any disagreements were adjudicated by a sen-
ior investigator. We used a standard protocol, form, and
database that collected the following information: first
author's name, article identification number, trial number
(if more than one trial was reported in a particular article),
condition under study (e.g. cardiovascular disease, can-
cer), country of first author's institution, continents from
which the participants were derived, total number of par-
ticipants randomized, number and percent of male partic-
ipants, age of participants (mean, median, standard
deviation, range, reported categories), race of participants
(number and percent), and number of treatment arms.
For each arm, the following information was collected:
number of participants; description of treatment provided
(i.e. drug, medical device, surgical procedure); and gen-
der, age, and race of participants.
The use (or non-use) of HTE analysis was the primary out-
come. In addition, we also examined the presence of sub-
group-only analysis, and either subgroup or HTE analysis,
as secondary outcomes. Subgroup-only analyses represent
missed opportunities on the path to understanding HTE;
with minor effort, studies that reported subgroup-only
analyses could have conducted formal HTE analyses and
provided direct information on HTE. The additional step
(of conducting a formal HTE analysis as opposed to a sub-
group-only analysis) is important because it will provide
important hypothesis-generating information for future
studies. We therefore identified all trials as reporting
either (1) HTE analysis, utilizing a formal test for hetero-
geneity or interaction; (2) subgroup-only analysis, with
no formal statistical tests for heterogeneity or interaction,
or (3) neither. For trials that reported HTE analysis, the
covariates examined were also recorded. These covariates
were later categorized by one investigator with consulta-
tion from a second as needed, into the following catego-
ries: age, gender, race/ethnicity, center/trial site/country,
individual clinical risk factor, multivariable risk index, co-
occurring treatment, comorbidity, and socioeconomic sta-
tus (income, marital status, and education). Individual
clinical risk factors were further categorized as being
related to prognosis, treatment responsiveness, or treat-
ment vulnerability [2]. We also coded whether the authors
presented information using a Forest Plot (a graph depict-
ing subgroup results as point estimates [boxes] and confi-
dence intervals [lines]) [38].
Potential predictors of HTE and subgroup-only analysis
included journal name, year, condition studied, geo-
graphic region of the first author's home institution, trial
design (either parallel or crossover RCT), and sample size
(in quintiles). We expected that different journals might
have different reporting policies, possibly influenced by
prevailing norms of the country of publication, which in
turn might be confounded with the first author's geo-
graphic region. We also hypothesized that HTE analysis
might increase over time as CONSORT standards were
disseminated, and that HTE analysis would increase with
sample size. The revised CONSORT standards [18] made
Guidelines for Journal Editors and Authors for Reporting and Interpreting HTE Analyses Figure 2
Guidelines for Journal Editors and Authors for Reporting and Interpreting HTE Analyses.
Guidelines for Journal Editors: 
x Recognize that interpreting subgroup analysis without a 
statistical test of heterogeneity or interaction is not good 
practice.
x Encourage authors to supply the following information in 
the paper or in an electronic appendix available to all 
readers:
o A list of all variables examined for HTE; 
o Effect sizes, confidence intervals, and statistical 
significance for all subgroups examined; 
o A clear description delineating which variables 
were pre-specified and which were exploratory 
(post hoc); 
o Exact p-values for tests of interaction or 
heterogeneity. 
Guidelines for Authors: 
x Recognize that interpreting subgroup analysis without a 
statistical test of heterogeneity or interaction is not good 
practice.
x Provide a clear statement regarding both clinical and 
statistical significance for any analyses involving 
interaction or heterogeneity. 
x Supply readers with a conclusion regarding heterogeneity 
and interaction effects based on the following:
o Evidence is sufficient to guide different treatment 
recommendations in one or more subgroups;
o Evidence is insufficient to guide different treatment 
recommendations for one or more subgroups, but 
sufficient to warrant future research with pre-
specified hypotheses;
o Evidence is sufficient to recommend uniform 
treatment across all subgroups;
o Evidence is insufficient to draw any conclusions 
about HTE.Trials 2009, 10:43 http://www.trialsjournal.com/content/10/1/43
Page 8 of 12
(page number not for citation purposes)
a clear distinction between subgroup and HTE analysis,
citing a test of interaction as the correct, and stronger, ana-
lytic technique. The Statement elaborated on the original
1996 guidelines, and emphasized the incorrectness of
comparing subgroup-specific p-values as a method of
inferring treatment heterogeneity. Thus, we expected to
see in increase in HTE analysis subsequent to 2001, with
a concomitant decrease in subgroup analyses. Finally, we
hypothesized that trials of common conditions with well-
defined prognostic indicators might be more likely to
evaluate these indicators.
Data Analysis
The relationships of HTE reporting with study characteris-
tics were assessed in two-way contingency table analyses
by using Pearson Χ2 tests or Fisher's exact test when sam-
ple size was small, while trends (where appropriate) were
assessed using the Mantel-Hantzel Χ2 test for trend. Logis-
tic regression was used to determine predictors of HTE
analysis. Significance of study characteristics in relation to
use of HTE analysis was assessed with a Wald Χ2 test. To
further explore HTE reporting characteristics, we sepa-
rately examined the association between study character-
istics (other than sample size) and HTE reporting in
articles above and below the median sample size (262
subjects). Wald Χ2 tests were used to determine significant
differences among these categories. SAS version 9 was
used for all computations [39].
We conducted two sensitivity analyses. First, to assess
whether our results were sensitive to possible clustering
effects arising from multiple trials per article, we re-ran the
logistic regression analysis after randomly selecting only
one trial from each article that reported on more than one
trial. Second, we recalculated reporting of HTE and sub-
group analysis after restricting our analysis to those trials
meeting specific sample size criteria (overall sample size
greater than 250 and at least 100 participants per arm,
making reasonably-powered subgroup analyses feasible).
Furthermore, we recalculated results for gender and race/
ethnicity after restricting to trials with an overall sample
size greater than 250, at least 100 participants per arm,
and at least 25% participants in the second largest gender
or racial/ethnic subgroup.
Results
Out of the 379 articles identified by our search, 303 met
our inclusion criteria and 76 did not (Figure 1). Some arti-
cles reported more than one trial, and abstraction
occurred on the trial level. Thus, the 303 eligible articles
represented 319 eligible RCTs. Twelve articles reported on
more than one trial: ten articles reported on two trials
each, and two articles reported on four trials each. Eighty-
six trials were excluded, including 77 from the 76 ineligi-
ble articles, and 9 from the 303 eligible articles. (An eligi-
ble article could contain both eligible and ineligible trials;
we kept the eligible trials and excluded the ineligible trials
in these articles.) The most common reason for exclusion
was a trial design other than RCT (n = 61 trials), typically
a cohort or case control design. The next most common
reason was unit of randomization other than the individ-
ual or treatment episode within an individual (n = 25 tri-
als).
Among the 319 eligible trials, cardiovascular (23%) and
infectious (22%) diseases were the most frequently stud-
ied conditions (Table 1). Sixty-two percent of first authors
were from regions outside North America. Parallel group
designs were far more prevalent than crossover designs.
Trial size ranged from 6 to 41,000 participants (median
262, inter-quartile range 101 to 708). Ninety-two trials
(29%) reported HTE analyses that used a test for heteroge-
neity or interaction; 88 (28%) reported subgroup-only
analysis without a statistical test for HTE/interaction; and
139 (44%) reported neither type of analysis. Graphical
display of HTE and subgroup effects using Forest Plots was
seen in 13/92 (14%) of trials reporting HTE analysis and
5/88 (5.6%) of trials reporting subgroup-only analysis.
Among studies reporting HTE analysis on at least one
named covariate (n = 91), 47% analyzed one covariate,
26% analyzed 2–4 covariates, 19% analyzed 5–10 covari-
ates, and 8% analyzed more than 10 covariates. Individ-
ual risk factors for disease occurrence or progression (e.g.
smoking status, creatinine level, CD4 count) were ana-
lyzed in 56% of studies, age in 29%, study site or region
in 29%, concurrent treatment in 25%, and comorbid
medical conditions in 21%. The 51 articles that reported
HTE based on individual risk factors for disease occur-
rence or progression examined a total of 159 variables. Of
these variables, 91% were prognostic risk factors, 25%
were related to treatment responsiveness, and 4% were
factors related to vulnerability to adverse outcomes (some
RCTs examined multiple individual clinical risk factors).
Treatment by gender interactions were evaluated in 30%
of studies in which both genders participated; treatment
by race/ethnicity interactions were assessed in 7% of stud-
ies involving more than one race/ethnicity. Despite
increased recognition of the value of multivariable risk
indices in HTE analyses [6,9,40-43] only three studies [44-
46] evaluated outcomes of treatment stratified by multi-
variable risk. When examined by sample size quintile, we
found that even studies in the smallest quintile (median =
37 participants) examined up to 9 covariates for HTE.
In the two-way contingency table analysis, performing an
HTE analysis was significantly associated with journal of
publication (p < 0.05); first author's region (p < 0.01);
and sample size (p < 0.0001 for trend) (Table 2). North
American journals and first authors were more likely toTrials 2009, 10:43 http://www.trialsjournal.com/content/10/1/43
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publish trials with HTE analysis. While the association
between HTE analysis and sample size is intuitive, HTE
analysis was reported in only 52% of studies within the
largest sample size quintile (Table 2). There was also a sig-
nificant trend toward more HTE analysis over time (p =
0.047). Subgroup analysis only (without an appropriate
statistical test for heterogeneity or interaction) was
observed in 29% of parallel group trials and in no crosso-
ver trials. In the two-way contingency table analysis, sub-
group analysis only was not significantly associated with
any of the study characteristics (data not shown).
Using multiple logistic regression to examine trial year,
journal of publication, clinical condition, first author's
trial region, and sample size, only sample size and journal
of publication were significant predictors of HTE analysis;
we found no significant trend over time (p = 0.52) (Table
3). The adjusted odds ratios comparing the top quintile of
sample size (median = 1560) to the bottom quintile
(median = 37) was 7.5 (95% confidence interval, 2.9–
19.3). For journal, the adjusted odds ratio for Annals of
Internal Medicine was 4.2 (95% CI, 1.2–15.1) and for
JAMA was 4.4 (95% CI, 1.4–13.5), with BMJ as the refer-
ence group. Restricting the analysis to trials above the
median sample size (n ≥ 262 subjects), 42% of trials per-
formed HTE analysis (35% in the 3rd quartile, 48% in the
4th quartile; data not shown in tabular form). Random
selection of only one trial per article (to avert any possible
clustering effect) did not materially alter the results of the
logistic regression analysis.
In the sensitivity analysis, there were 153 studies with
sample size of at least 250 with a minimum of 100 sub-
jects per trial arm. Sixty-one of these trials (40%) reported
HTE analysis, 47 (31%) reported subgroup analysis only,
and 45 studies (29%) did not report either type of analy-
sis. Among 104 trials with at least 25 male subjects and 25
female subjects per arm, 14 trials (13.5%) examined gen-
der for HTE, compared with 3/33 (9%) among those not
meeting these minimal sample size criteria. Only 5/34
(15%) of trials meeting minimal sample size criteria for
race/ethnicity (see Methods) conducted an HTE analysis
with respect to race/ethnicity.
Discussion
This review of 319 RCTs published in five prominent gen-
eral medical journals is the most comprehensive to date,
and the only one that examines trends of HTE reporting
over time. The results suggest that reporting on HTE
occurs in less than one-third of studies published in
prominent general medical journals, and were only mar-
ginally better in 2004 than in 1994. Overall, less than one-
third of studies in our sample reported HTE analysis, a
result consistent with previous, less comprehensive
reviews. Another 28% reported subgroup-only analyses
without formal statistical tests for HTE/interaction.
These trials are missed opportunities. With minimal addi-
tional effort, they could have added statistical tests for
HTE or interaction in addition to the subgroup results that
they reported, nearly doubling the proportion of HTE
analyses and enriching the literature with much-needed
HTE information. Such tests are critical for appropriate
interpretation of results, as differences in subgroup-spe-
cific point estimates are meaningful only when evaluated
alongside their corresponding confidence intervals.
Considering both HTE analyses and subgroup-only anal-
yses, 57% of the trials in our review reported some kind of
subgroup analysis, a proportion that increased to about
three-quarters if we examine only the largest trials. Previ-
ous research reported equal [34] or higher [27,32,33,35]
proportions, possibly because of restriction to trials of a
minimum sample size, a specific discipline, or a specific
journal.
The biostatistical literature tends to view subgroup analy-
sis skeptically, often citing the dual problems of multiple
statistical comparisons and low power [16,47]. This view
is likely reinforced by the impression that the analyses
themselves are poorly performed. Our results support this
judgment. Wang et al. [35] recently outlined detailed
guidelines for reporting subgroup analyses in manu-
scripts, including specific information that authors should
include, by section. We present complementary guide-
lines in Figure 2, and emphasize the role of journal editors
in setting appropriate standards for subgroup analysis
reporting. There are three major principles to our guide-
lines. The first and second underscore the CONSORT rec-
ommendations [18] that (1) proper HTE analysis requires
statistical tests of interaction or heterogeneity and (2) that
all variables examined for HTE should be labeled as pre-
specified or post hoc and reported in the body of the
paper or in an electronic appendix. Finally, we advocate
for authors explicitly considering the clinical and statisti-
cal significance of results obtained, and provide recom-
mendations for future research and clinical practice. In
addition, when the purpose of HTE analysis is hypothesis
generation, it may make sense to accept a more lenient
standard of statistical significance (i.e. 0.10). Reporting
only subgroup-specific effects without an appropriate test
of heterogeneity or interaction can be misleading [24]. Yet
identifying potential moderators of treatment effects is
critical to patient-centered, individualized care
[2,8,25,48]. Inconsistent reporting of subgroup analysis
not only impairs recognition of patients who may
respond better or worse than average, but also impedes
hypothesis generation and stifles future research.
Although tests for heterogeneity and interaction have low
power for detecting modest but potentially clinically
important subgroup differences, they represent a conserv-
ative approach and provide a brake on the tendency to
over-interpret observed subgroup differences. However, itTrials 2009, 10:43 http://www.trialsjournal.com/content/10/1/43
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is important to conduct HTE analysis with caution and
not over interpret the results. It is necessary to recognize
that post hoc HTE analyses are for hypothesis generation
and to aid in the design of future confirmatory studies,
that significant effects may be a result of intra-individual
variability, and that the results of such analyses should
not be used to promote different treatment recommenda-
tions.
Among trials that explored heterogeneity of treatment
effects, clinical prognostic factors were evaluated fre-
quently; age, gender, and site factors less often; and race/
ethnicity rarely. Even among those trials with a sample
size adequate for exploring HTE by race/ethnicity, only
7% of trials did so. The limited attention to race/ethnicity
is puzzling for two reasons. First, the literature provides
examples in which race/ethnicity influences baseline risk
of a disease [49], responsiveness to treatment [50], and
vulnerability to adverse outcomes [51]. Second, growing
interest in genomics might be expected to stimulate inter-
est in the treatment-modifying effects of genetic proxies,
including imperfect ones like race/ethnicity. Consistent
with Parker et al. [27], we found little use of multivariate
risk stratification, an approach that may greatly increase
statistical power for detecting HTE [48].
More frequent HTE analysis in North American journals
may reflect differences in biostatistical perspectives or bio-
medical culture. The dominant norm tends to be more
conservative in Europe and especially in Britain, perhaps
as a result of public payment for care, which demands a
higher standard of evidence before treatments are widely
accepted and delivered [52-54]. The trend for increased
HTE analysis between 1994 and 2004 may be attributable
to the revised CONSORT recommendations and a grow-
ing awareness of the potential of such analyses. The rela-
tively infrequent use of Forest Plots, even among studies
reporting HTE analysis, is regrettable because these plots
are a simple, compact, and readily understood method of
presenting potential moderators.
Our results should be interpreted in light of several limi-
tations. First, we reviewed a limited number of trials. It is
possible that subgroup-specific trials were published in
other journals, or during months or years that we did not
sample. However, our sample included five large-circula-
tion, high-impact journals with strict peer-review stand-
ards, so our sample should be representative of well-
designed clinical trials that generalist clinicians are most
likely to read and that major news media are most likely
to publicize. Second, it is possible that some trials con-
ducted HTE analysis but did not report it because the
results were not statistically significant. However, even
non-significant data are useful for the purposes of hypoth-
esis generation and, arguably, authors should report any
HTE analysis, significant or not, and especially when the
analysis is pre-specified. Third, our standards for HTE
reporting may not reflect journals' own standards for HTE
reporting. A more conservative statistical review process
may result in reduced HTE reporting, regardless of the
analysis actually conducted in the study. Finally, our rec-
ommendations for authors and editors are based on an
informal procedure, and should be interpreted in light of
this limitation. Further refinement of the recommenda-
tions may be necessary before adoption by editors and
authors.
Conclusion
Our findings indicate that HTE reporting in the general
medical literature is neither rigorous nor routine. Given
the increasing recognition of HTE [2,3,25], it may be time
to develop standards for reporting of exploratory and con-
firmatory HTE analysis. In 1994, the National Institutes of
Health mandated the inclusion of women and racial/eth-
nic minorities in research populations and, in 2000, sup-
plemented that recommendation with guidelines
regarding the reporting of subgroup-specific results of
Phase III Clinical Trials [55]. Although these guidelines
included a recommendation that investigators report both
significant and non-significant results, our data show only
modest progress toward that goal. Highlighting variables
that deserve further exploration is a first step in identifying
groups that may or may not respond better to a given ther-
apy [56]. Because trials in more responsive subgroups
have lower sample size requirements, identifying these
groups through exploratory subgroup analysis could facil-
itate relatively cost-effective confirmatory trials. An itera-
tive process of exploratory followed by confirmatory HTE
analysis may not only quicken the cycle of discovery but
also inform clinical judgment.
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